CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
FMISO +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00902577
NCT00902577Phase 2Completed
CompareCT.gov

Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI

National Cancer Institute (NCI)·interventional·Posted May 15, 2009·Updated Apr 8, 2019

In Brief

A Phase 2 clinical trial evaluating FMISO, MRI, and 2 other interventions for Adult Giant Cell Glioblastoma and 2 related conditions. Completed, enrolled 50 participants across 14 sites.

Detailed Summary

This phase II trial is studying how well positron emission tomography (PET) scan using 18F-fluoromisonidazole works when given together with magnetic resonance imaging (MRI) ) in assessing tumor hypoxia in patients with newly diagnosed glioblastoma multiforme (GBM). Diagnostic procedures, such as MRI and PET scan using 18F-fluoromisonidazole (FMISO), may help predict the response of the tumor to the treatment and allow doctors to plan better treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 15, 2009
Enrollment StartAug 24, 2009
Primary CompletionJan 31, 2018
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 17.1 years ago

Interventions

FMISOdrug

FMISO PET scans

MRIother

Undergo MRI

PETother

Undergo FMISO PET scan

MRSother